Biotech Scholar Rock to webcast Jefferies healthcare talk June 3
Scholar Rock (NASDAQ: SRRK) announced that its management will participate in the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET. The company, which specializes in therapies for spinal muscular atrophy and other neuromuscular diseases, will provide a live webcast of the presentation. A replay will also be available on Scholar Rock's investor relations website for approximately 90 days following the event.
Charles Schwab Investment Management Inc. Acquires 25,060 Shares of Scholar Rock Holding Corporation $SRRK
Charles Schwab Investment Management Inc. increased its stake in Scholar Rock Holding Corporation by 3.7% in the fourth quarter, acquiring an additional 25,060 shares, bringing its total holdings to 702,095 shares valued at $30.9 million. Wall Street analysts maintain a generally bullish outlook on SRRK, with a consensus "Buy" rating and an average target price of $56.00. The article also notes recent insider sales by the CEO and CFO, which were attributed to tax withholding obligations related to equity awards.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock announced new inducement equity awards for six newly hired employees, totaling 38,481 shares of common stock. These grants, comprising stock options and restricted stock units, are issued under the company's 2022 Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are designed to attract new talent, with specific vesting schedules for both the stock options and restricted stock units.
Redmile Group owns 7.6% of Scholar Rock (SRRK) via funds and affiliates
Redmile Group, through its various funds and affiliates, reported a 7.6% beneficial ownership stake in Scholar Rock Holding Corporation (SRRK), totaling 9,066,621 shares of common stock. This ownership is based on 119,103,774 shares outstanding as of March 31, 2026. The filing, an amendment to a prior Schedule 13G/A, indicates shared voting and dispositive power, with Redmile and Jeremy C. Green disclaiming beneficial ownership except for any pecuniary interest.
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises
Scholar Rock (SRRK) reported a Q1 2026 EPS of -$0.83, missing the -$0.80 forecast, yet its stock rose 2.72% in pre-market trading due to positive market reaction to strategic updates. The FDA has accepted a Biologics License Application for apitegromab with a PDUFA date of September 30, 2026, and the company maintains a strong cash position of $480 million to support its commercial launch readiness in the U.S. and Europe. Scholar Rock is also advancing its anti-myostatin pipeline with other programs for SMA and FSHD, aiming to address significant unmet medical needs.
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises
Scholar Rock (SRRK) reported a Q1 2026 EPS of -$0.83, missing analyst forecasts, yet its stock rose 2.72% in pre-market trading, driven by the FDA's acceptance of the Biologics License Application for apitegromab with a PDUFA date of September 30, 2026. The company discussed its strong cash position of $480 million and significant progress in commercial readiness for apitegromab in both U.S. and European markets. Management expressed confidence in a successful launch of its SMA treatment, emphasizing strategic advancements despite the EPS miss.
TradingKey
This page provides an overview of Scholar Rock Holding Corp (SRRK) on the TradingKey platform, including its market data, such as its current price of $48.360 and a slight decrease of 0.06%. The content highlights the stock's market capitalization of $5.76 billion and offers sections for financials, discussions, and analysis, but the specific details of these sections are not provided. The page also mentions tools like stock screener and economic calendar and has disclaimers about delayed data and investment risks.
Number of shareholders of Scholar Rock Holding Corp. – FWB:2QK
The article provides a financial overview page for Scholar Rock Holding Corp. (FWB:2QK) on TradingView, specifically focusing on the number of shareholders. It includes market data, reference data, and links to SEC filings, but does not present the shareholder number itself, instead offering a placeholder for "Period," "Value," "Change," and "Change %".
Is Scholar Rock Holding (SRRK) Offering Value After Its Strong Multi Year Share Price Gains
Scholar Rock Holding (SRRK) has experienced mixed recent returns but has seen significant multi-year gains. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 70.5%, with a projected intrinsic value of $157.25 per share. However, its Price-to-Book (P/B) ratio of 20.08x indicates it may be overvalued when compared to the biotech industry average and its own "Fair Ratio" framework.
Scholar Rock (NASDAQ:SRRK) Issues Quarterly Earnings Results
Scholar Rock (NASDAQ:SRRK) reported quarterly earnings of ($0.83) per share, slightly missing the consensus estimate and worsening from the previous year. Despite the earnings miss, the company announced that the FDA accepted its Biologics License Application (BLA) for apitegromab to treat spinal muscular atrophy, setting a PDUFA action date of September 30, 2026. The stock saw a 4.2% increase, and analysts maintain a "Buy" rating with a consensus price target of $56.00, while insider selling was noted to cover tax obligations.
SRRK Maintained by Barclays -- Price Target Raised to $55
Barclays analyst Etzer Darout has raised the price target for Scholar Rock Holding (SRRK) to $55, maintaining an Overweight rating due to the company's progress in developing therapies for rare neuromuscular diseases. Despite this positive outlook, the company has a low GF Score™ of 31/100, indicating financial weaknesses, and has seen significant insider selling worth $5.0 million over the last three months. Investors are advised to consider these mixed signals cautiously.
Scholar Rock (SRRK) Receives Positive Catalyst Watch from JPMorg
JPMorgan has initiated a "Positive Catalyst Watch" on Scholar Rock Holding Corp (SRRK), assigning an Overweight rating and a $56 target price following the FDA's acceptance of the company's apitegromab application for spinal muscular atrophy. While this presents a potential upside catalyst, investors are cautioned by the company's low GF Score of 31/100, which indicates below-average financial performance, and $5.0 million in insider stock sales over the last three months. The FDA is expected to make a decision by September 30, with analysts optimistic about approval.
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock announced its Q1 2026 financial results and business highlights, including the FDA's acceptance of apitegromab's Biologics License Application (BLA) for spinal muscular atrophy (SMA) with a PDUFA date of September 30, 2026. The company reported a net loss of $105.5 million for the quarter and holds $479.9 million in cash, cash equivalents, and marketable securities. Scholar Rock is also progressing with its European regulatory review for apitegromab and advancing other pipeline candidates like SRK-439 and apitegromab for FSHD.
Q1 2026 Scholar Rock Holding Corp Earnings Call Transcript
This document contains the Q1 2026 earnings call transcript for Scholar Rock Holding Corp (SRRK). The call took place on May 7, 2026, and featured remarks from CEO David Hilal, R&D President Akshay Vaishna, COO Keith Woods, and CFO Vikas Sinha, covering business updates, R&D progress, commercial readiness, and financial performance.
Scholar Rock Q1 2026 Earnings Call Transcript
Scholar Rock announced that the FDA accepted its Biologics License Application (BLA) for apitegromab to treat children and adults with Spinal Muscular Atrophy (SMA), setting a PDUFA action date of September 30, 2026. The BLA includes two fill-finish facilities, providing parallel paths for approval, despite an unannounced re-inspection of one facility. The company continues to advance its clinical pipeline, including a phase II study for Facioscapulohumeral Muscular Dystrophy (FSHD) and a subcutaneous apitegromab formulation, and ended Q1 2026 with $480 million in cash, signaling strong financial readiness for an anticipated launch in the U.S. and Europe.
Earnings Flash (SRRK) Scholar Rock Posts Q1 Net Loss $0.83 a Share, vs. FactSet Est of $0.80 Loss
Scholar Rock Holding Corporation (SRRK) reported a Q1 net loss of $0.83 per share, which is higher than the FactSet estimate of a $0.80 loss. The company is a biopharmaceutical firm focused on developing treatments for serious diseases involving protein growth factors, with primary product candidates apitegromab for spinal muscular atrophy and SRK-181 for cancers. The article also provides recent news, analyst ratings, and company financial overviews.
Scholar Rock gets Sept. 30 FDA decision date for SMA drug
Scholar Rock announced that the FDA has accepted its Biologics License Application (BLA) for apitegromab, a drug to treat spinal muscular atrophy (SMA), setting a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2026. The company also reported its first-quarter 2026 financial results, with $480 million in cash and cash equivalents, and confirmed preparations for a U.S. commercial launch upon FDA approval, alongside ongoing regulatory review in Europe.
Scholar Rock (NASDAQ: SRRK) details March 31 2026 quarter
Scholar Rock (NASDAQ: SRRK) announced its financial results for the quarter ended March 31, 2026, reporting a net loss of $105.5 million. The company highlighted the FDA's acceptance of its apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) with a PDUFA action date of September 30, 2026, and is actively preparing for a U.S. launch. Additionally, Scholar Rock provided updates on its pipeline, including the ongoing Phase 2 OPAL study for apitegromab in SMA patients and the anticipated initiation of the Phase 2 FORGE trial for apitegromab in facioscapulohumeral muscular dystrophy (FSHD) in mid-2026.
Scholar Rock faces earnings test as apitegromab approval looms By Investing.com
Scholar Rock Holding Corp is set to report its first-quarter results, with analysts expecting a loss of 80 cents per share. The biotech company is focused on the regulatory approval of apitegromab for spinal muscular atrophy, with a PDUFA action date in late September 2026. Investors will be looking for updates on FDA interactions and commercialization plans, as the company prepares for a potential commercial launch in late 2026.
Scholar Rock faces earnings test as apitegromab approval looms
Scholar Rock Holding Corp is set to report its first-quarter results, with analysts expecting an 80-cent loss per share. The company is nearing a critical regulatory decision for its lead candidate, apitegromab, a potential treatment for spinal muscular atrophy, with a PDUFA action date expected in late September 2026. Investors will be focused on updates regarding the regulatory review, commercial launch preparations, and the company's cash burn rate as it moves towards potential product revenue.
Evercore ISI initiates Scholar Rock stock coverage with outperform rating
Evercore ISI has initiated coverage on Scholar Rock Holding Corp. (NASDAQ:SRRK) with an "outperform" rating and a $65.00 price target, citing apitegromab's potential as a de-risked, muscle-directed asset. The firm anticipates regulatory approval in 2026 and a commercial ramp-up in the second half of 2027. This positive outlook follows Scholar Rock's resubmission of its Biologics License Application for apitegromab and upgrades from other financial institutions.
Jennison Associates LLC Acquires 1,188,676 Shares of Scholar Rock Holding Corporation $SRRK
Jennison Associates LLC significantly increased its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 74.0% in Q4, acquiring an additional 1,188,676 shares. This brings their total holdings to 2,795,188 shares, valued at approximately $123.1 million. Insider selling occurred in April to cover tax withholding, while Wall Street analysts maintain a consensus "Buy" rating with an average target price of $55.40.
Scholar Rock (SRRK) Projected to Post Earnings on Thursday
Scholar Rock (SRRK) is projected to release its Q1 2026 earnings before market open on Thursday, May 7th, with analysts expecting an EPS of ($0.82) and revenue of $5.0 million. The company previously beat estimates in its last quarter. Analyst sentiment is largely positive, with an average "Buy" rating and a consensus price target of $55.40.
Scholar Rock will webcast its BofA health care conference talk May 12
Scholar Rock (NASDAQ: SRRK) announced that its management will present at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. A live webcast of the presentation will be available on the "Events and Presentations" page of the company's investor relations website, with a replay accessible for approximately 90 days. The biopharmaceutical company focuses on developing treatments for spinal muscular atrophy (SMA) and other neuromuscular diseases, leveraging its platform in myostatin biology.
Pictet Asset Management Holding SA Sells 126,964 Shares of Scholar Rock Holding Corporation $SRRK
Pictet Asset Management Holding SA reduced its stake in Scholar Rock Holding Corporation by 9.6% in the fourth quarter, selling 126,964 shares and now owning 1.17% of the company. Company insiders, including CEO David Hallal, also sold shares to cover tax obligations. Despite these sales, Scholar Rock maintains a "Buy" consensus rating from analysts, with an average price target of $55.40, and the stock is largely held by institutional investors.
SRRK SEC Filings - Scholar Rock Holding 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Scholar Rock Holding (SRRK) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading documents. It details how Stock Titan offers access to regulatory disclosures, AI-powered summaries, and real-time updates from EDGAR to assist investors in analyzing the company's financial condition, clinical progress, and corporate strategy. Recent filings highlighted include those related to apitegromab, equity offerings, and director stock transactions.
Scholar Rock (SRRK) director exercises options for 89,800 new shares
Scholar Rock Holding Corp director Kristina Burow exercised stock options to acquire 89,800 shares of common stock on April 23, 2026, at various exercise prices. Following these transactions, Burow directly holds 110,871 common shares, while an entity linked to her, ARCH Venture Fund VIII, L.P., indirectly holds 2,345,711 common shares. The filing indicates these were option exercises with no reported same-day sales.
Don't Ignore The Insider Selling In Scholar Rock Holding
The CEO & Chairman of Scholar Rock Holding, David Hallal, recently sold shares worth US$1.5m, representing 7.1% of his holding. While this specific sale is noted, the article highlights that insider buying over the last year, including a significant purchase by Srinivas Akkaraju, suggests insiders still view the stock positively at certain price points. Insiders collectively own 1.3% of the company, indicating a reasonable alignment with shareholder interests despite the recent selling activity.
Scholar Rock Holding Corp ($SRRK) CEO and Chairman 2025 Pay Revealed
Scholar Rock Holding Corp's CEO and Chairman, David Hallal, is estimated to have received $33,300,927 in compensation in 2025 based on a recent SEC filing. The article also details significant insider selling activity, hedge fund movements in SRRK stock, and recent analyst ratings and price targets for the company.
Scholar Rock (SRRK) details 2026 virtual meeting, director elections and auditor ratification
Scholar Rock Holding Corporation (SRRK) announced details for its 2026 virtual Annual Meeting of Stockholders on June 4, 2026, where shareholders will vote on the election of four Class II directors, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm, and a non-binding advisory vote on executive compensation. The meeting will be held online, and voting will be available through various digital and traditional methods. The Board of Directors unanimously recommends voting "FOR" all three proposals, and the proxy statement includes extensive details on corporate governance, director biographies, executive compensation, and related party transactions.
SRRK Initiates Coverage by Canaccord Genuity -- Price Target Ann
Canaccord Genuity has initiated coverage on Scholar Rock Holding (SRRK) with a "Buy" rating and a price target of $62.00, significantly higher than its current trading price. Despite this positive outlook and the company's biopharmaceutical pipeline targeting rare neuromuscular diseases, SRRK has a low GF Score™ of 30 due to concerns in profitability and growth, and has seen notable insider selling of $5.7 million in the past three months. Investors are advised to consider both the growth potential and these red flags.
Scholar Rock CEO David Hallal sells $1.5m in company shares
Scholar Rock CEO David Hallal sold $1.5 million worth of company shares to cover tax obligations related to the vesting of restricted stock units. This "sell to cover" transaction is mandated by the company's equity incentive plans, and Hallal still retains a significant direct and indirect holding in Scholar Rock. The company has also resubmitted its Biologics License Application for apitegromab to the FDA, receiving positive analyst reactions and increased price targets.
[ARS] Scholar Rock Holding Corp SEC Filing
This article announces an ARS SEC filing by Scholar Rock Holding Corp (SRRK) from April 22, 2026. The filing is categorized as having a low impact and neutral sentiment. It also includes an overview of SRRK's stock rankings, recent news, and other SEC filings.
Vikas Sinha Sells 10,410 Shares of Scholar Rock (NASDAQ:SRRK) Stock
Scholar Rock's CFO, Vikas Sinha, sold 10,410 shares of NASDAQ:SRRK on April 16th for approximately $516,024, reducing his stake by 1.65%. This sale was primarily to cover tax withholding obligations related to equity awards. Despite this insider sale, analysts maintain a largely positive outlook on Scholar Rock, with a consensus "Buy" rating and an average price target of $55.40, following several recent price objective increases from various brokerage firms.
David Hallal Sells 30,615 Shares of Scholar Rock (NASDAQ:SRRK) Stock
Scholar Rock CEO David Hallal sold 30,615 shares of SRRK stock on April 16th for approximately $1.52 million to cover tax withholding obligations on vested equity awards, reducing his stake by 1.83%. Despite this insider sale, institutional investors hold over 91% of the stock, and analysts maintain a consensus "Buy" rating with an average price target of $55.40, with some firms raising targets up to $62. The company's shares are trading at $47.80, above its 50-day and 200-day simple moving averages.
Scholar Rock (NASDAQ:SRRK) COO Sells $506,605.40 in Stock
Scholar Rock's COO, Keith Woods, sold 10,220 shares of the company's stock for $506,605.40 to cover tax withholding obligations on vested awards, reducing his stake by 1.62%. The stock fell 4.3% to $47.80 following the transaction, but analysts maintain a "Buy" rating with an average price target of $55.40. The company reported better-than-expected EPS in its last quarter, and institutional investors have recently adjusted their positions.
Scholar Rock CFO Vikas Sinha sells $516,070 in shares
Scholar Rock's CFO, Vikas Sinha, sold 10,410 shares worth approximately $516,070 on April 16, 2026. This transaction was not discretionary but a "sell to cover" to meet tax withholding obligations from vesting restricted stock units. Recent company news includes the resubmission of a Biologics License Application for apitegromab, leading to positive analyst ratings and increased price targets.
Tax-driven share sale by Scholar Rock (SRRK) R&D president
Akshay Vaishnaw, President of R&D at Scholar Rock (SRRK), sold 12,246 shares of common stock for $49.5745 per share. This sale was a mandatory "sell to cover" transaction to satisfy tax withholding obligations on restricted stock units (RSUs) that vested on April 15, 2026, and was not a discretionary trade. After the sale, Vaishnaw directly holds 630,542 shares, along with additional vested and unvested RSU awards.
Tax-driven share sale by Scholar Rock (SRRK) CEO after RSU vesting
Scholar Rock Holding Corp's CEO, David Hallal, sold 30,615 shares of common stock for $49.5745 per share on April 15, 2026. This "sell to cover" transaction was mandated to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary trade. Following the sale, Hallal directly holds 1,639,034 shares and also has significant exposure through additional common stock and various RSU awards.
Scholar Rock R&D president sells $607,089 in stock
Akshay Vaishnaw, President of Research & Development at Scholar Rock Holding Corp (NASDAQ:SRRK), sold 12,246 shares of company stock for approximately $607,089. This "sell to cover" transaction was mandated to meet tax withholding obligations from restricted stock units (RSUs) and was not a discretionary trade. Following the sale, Mr. Vaishnaw still holds a significant number of shares and RSUs in the company.
Tax-driven share sale by Scholar Rock (SRRK) COO Keith Woods
Scholar Rock Holding Corp COO Keith Woods sold 10,220 shares of common stock for $49.5745 per share. This sale was a mandatory "sell to cover" transaction to fulfill tax withholding obligations from vesting restricted stock units (RSUs) on April 15, 2026, and was not a discretionary trade. After the transaction, Woods directly holds 620,055 shares and retains significant RSU holdings, aligning his compensation with the company's future performance.
Scholar Rock (SRRK) CFO executes 10,410-share tax sell-to-cover after RSU vesting
Scholar Rock Holding Corp's CFO, Vikas Sinha, sold 10,410 shares of common stock at $49.5745 per share on April 16, 2026. This transaction was a mandatory "sell to cover" to fulfill tax withholding obligations from restricted stock units (RSUs) that vested on April 15, 2026, and was not a discretionary trade. After the sale, Sinha's equity position in the company totals 619,856 equity-linked interests.
Scholar Rock COO Keith Woods sells $506,651 in company stock
Scholar Rock COO Keith Woods sold 10,220 shares of company stock for approximately $506,651, primarily to cover tax obligations related to vesting restricted stock units. This transaction occurred as the stock trades near its 52-week high, and an InvestingPro analysis suggests the stock is currently overvalued. The company also recently resubmitted its Biologics License Application for apitegromab, a treatment for spinal muscular atrophy.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock announced inducement equity awards to nine new employees, covering 89,304 shares of common stock. These awards consist of stock options and restricted stock units, vesting over several years and are granted under the Company's 2022 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for new hires to join Scholar Rock, a biopharmaceutical company focused on treatments for neuromuscular diseases.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Analysts
Scholar Rock Holding Corporation (NASDAQ:SRRK) has received a consensus "Buy" rating from seventeen analysts, with an average 12-month price target of $54.93. The company's shares opened at $50.00, demonstrating financial metrics such as a $5.74 billion market cap and a 52-week range of $27.07–$51.63. Despite insider selling activity, institutional investors hold a significant 91.08% stake in SRRK.
Nine new Scholar Rock hires receive equity awards tied to 89,304 shares
Scholar Rock (SRRK) granted inducement equity awards covering 89,304 shares of common stock to nine new employees, including stock options and restricted stock units. These awards, issued under the Company's 2022 Inducement Equity Plan, are designed to attract new talent and align with Nasdaq Listing Rule 5635(c)(4). The grants vest over several years, contingent on continued employment.
Scholar Rock investors get Q1 results before market open May 7
Scholar Rock (NASDAQ: SRRK) announced it will report its first-quarter 2026 financial results on Thursday, May 7, 2026, before market open. The biopharmaceutical company, focused on developing treatments for spinal muscular atrophy (SMA), will host a conference call and webcast with management at 8:00 a.m. ET. Investors can access the webcast via the company's website or register to participate by telephone.
Scholar Rock stock hits 52-week high at 51.31 USD
Scholar Rock Holding Corp's stock has reached a 52-week high of $51.50, reflecting a 104% one-year return and a 29% gain in the past six months, driven by investor confidence and advancing therapies. Despite trading above its Fair Value according to InvestingPro, the company has positively advanced its Biologics License Application for apitegromab and received increased price targets from Jefferies and BofA Securities. This positive outlook is further supported by the discontinuation of a competing drug's development.
A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk
Scholar Rock (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following facility remediation and the addition of a second fill-finish site. The company's shares have seen significant returns, and its valuation narrative suggests it is 11.4% undervalued with a fair value of $55.07, based on future revenue projections despite current lack of revenue. However, this valuation depends on timely regulatory clearance and controlled launch spending.
Mohammed Qatanani (NASDAQ: SRRK) files Form 144 to sell 23,408 shares via option exercise
Mohammed Qatanani, an insider at Scholar Rock Holding Corp (NASDAQ: SRRK), filed a Form 144 to sell 23,408 shares of common stock on April 6, 2026, through a stock option exercise for cash. The filing also revealed three prior sales within the last three months, totaling 36,494 shares. These sales include 13,112 shares on January 14, 2026, 14,898 shares on January 22, 2026, and 8,484 shares on February 23, 2026.
